Emergent Reports $400M in Mpox Outbreak Orders

Emergent BioSolutions, a prominent vaccine and antibody manufacturer, has recently secured approximately $400 million in orders for its smallpox and monkeypox (mpox) products. These orders include significant contracts for its ACAM2000 vaccine, which is being used to combat an mpox outbreak in Africa. The contracts are set for fulfillment in 2023 and 2024, with deliveries scheduled for this year and the next.

In 2023, Emergent BioSolutions obtained a $120 million contract to supply the U.S. Strategic National Stockpile with its ACAM2000 vaccine, designed for both smallpox and mpox. Additionally, the company secured a government contract earlier in the year worth over $250 million. This substantial agreement involves the provision of multiple products: the ACAM2000 vaccine, the immune globulin product CNJ-016, the Anthrax vaccine known as CYFENDUS, and the Botulism vaccine referred to as BAT.

Joe Papa, the CEO of Emergent BioSolutions, emphasized the company's commitment to addressing serious viral threats. "These incremental orders demonstrate our ongoing leadership to help address serious viral threats like smallpox and mpox," he stated in a press release.

By mid-October, Emergent had already delivered close to $210 million worth of ACAM2000 and CNJ-016 doses. Additionally, the company has over $185 million worth of vaccines still to be delivered within the calendar year. This highlights their significant role in the ongoing efforts to manage and mitigate viral outbreaks.

Emergent's involvement in combating the mpox outbreak began in August of this year when the company distributed 50,000 doses of the ACAM2000 vaccine to several African nations, including the Democratic Republic of the Congo, Burundi, Kenya, Rwanda, and Uganda. Initially, the ACAM2000 vaccine was approved solely for smallpox. However, in August, the FDA extended its approval to include mpox. This regulatory update coincided with the World Health Organization's declaration of mpox as a public health emergency, highlighting the urgency and importance of Emergent's mission.

In summary, Emergent BioSolutions has taken significant strides in responding to viral threats by securing substantial contracts and delivering critical vaccines. Their efforts, particularly in the context of the mpox outbreak in Africa, reflect their leadership and dedication to public health. The company's proactive distribution of vaccines and the regulatory updates enabling broader use of ACAM2000 underscore their pivotal role in addressing global health challenges.